Drug induced lichen planus like eruption is an uncommon cutaneous adverse effect of several drugs. This appears symmetric eruption of erythematous or violaceous plaques resembling lichen planus on the trunk and extremities. A 50-year-old male presented with scaly, violaceous plaques and dusky brown macules on whole body. For four months, the patient was treated with olmutinib, an oral, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor. In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. The biopsy specimen from the patient showed features of lichen planus. We diagnosed him with olmutinib-induced lichen planus like eruption. He was treated with oral methylprednisolone and topical desoxymethasone 0.25% ointment. At the same time, olmutinib dose was decreased to threefourths of this patient's starting dose. After that, the cutaneous lesions improved. (Ann Dermatol 30(4) 451∼453, 2018) 
INTRODUCTION
Olmutinib is an oral, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer. This received its first global approval in South Korea in May 2016 1 . We present a case of lichen planus (LP) like eruption in a man after olmutinib treatment. To our knowledge, this is the first reported case of olmutinib induced LP like eruption.
CASE REPORT
A 50-year-old male presented with scaly, violaceous plaques and dusky brown macules on whole body for one month (Fig. 1A) . Flexural areas were spared (Fig. 1B) . There was no mucous membrane lesion. The patient had been treated with olmutinib for four months because of non-small cell lung cancer. Pleural and brain metastasis were found at the time of diagnosis. Therefore, clinical trial with olmutinib for palliative chemotherapy was performed with patient consent. No other medication was used to this patient within three months. Skin biopsy specimen of his dorsum of hand demonstrated focal orthokeratosis, wedge-shaped hypergranulosis, saw-toothed irregular elongated rete ridges, and dermal lichenoid lymphocytic infiltration with scanty eosinophils. Max-Joseph space and dyskeratotic cells were also shown in the specimen (Fig. 2 ). These histologic features resembled those of LP. However, the clinical features were different from typical features of idiopathic LP, and the cutaneous lesions appeared after olmutinib therapy. Consequently, we diagnosed this olmutinib induced LP like eruption. He was treated with oral methylprednisolone 20 mg per day initially. Every three days, the dosage of methylprednisolone was reduced in half than before. Topical desoxymethasone 0.25% ointment was also applied to his lesions. At the same time, olmutinib dosage was decreased to threefourths of this patient's starting dose (800 mg per day to 600 mg per day), because the oncologist considered this cutaneous reaction as grade III adverse event. After three weeks, the body surface area of cutaneous lesions decreased to about a half. After the discontinuation of systemic corticosteroid therapy, he was treated with oral antihistamine, topical steroid and tacrolimus ointments for several weeks because of itch. Although the dosage of olmutinib has been maintained 600 mg per day for four months, new lesions have not appeared.
DISCUSSION
Drug induced LP like eruption is an uncommon cutaneous adverse event of several drugs such as antimalarial, beta-blockers, gold salts, methyldopa, or quinidine 2 . Latency period varies from months to a year or more. It depends upon the class of drug, dose, host reaction, and concurrent medications 3 . Typical cutaneous lesion of drug induced LP like eruption is symmetric eruption of erythematous or violaceous plaques on the trunk and extremities resembling idiopathic LP. However, drug induced LP like eruption rarely shows the flexural distribution which is common in idiopathic LP. Furthermore, mucous membrane involvement is less common in drug induced LP like eruption 4 .
In this case, skin lesions developed after the initiation of olmutinib therapy and improved after decreasing of dosage of olmutinib. Flexural areas were spared. Furthermore, mucous membranes were not involved. . Theoretically, olmutinib should have minimal effect to normal skin, but LP like eruption was occurred in our case. Serious cutaneous adverse events of olmutinib, toxic epidermal necrolysis and Stevens-Johnson syndrome, also became an issue a few months ago. Therefore, we claim that clinicians should be aware of the risk of cutaneous adverse events of olmutinib.
